MorphoSys AG Reports Outcome Of Annual General Meeting 2017 Post author:Sam Post published:May 16, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Acorda Investor Urges for Company to Explore Sale August 6, 2017 Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017 Galapagos' Phase II Results With GLPG1690 are 'Extremely Exciting' August 9, 2017
Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017